Resources Repository
-
ArticlePublication 2016Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and …
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and middle-income countries (LMICs). As part of the Disease Control Priorities Three (DCP3) Study efforts addressing quality improvement, the authors reviewed and summarized currently available evidence on interventions to improve quality of clinic-based CVD prevention and management in LMICs. Using a narrative review of published comparative clinical trials that evaluated efficacy or effectiveness of clinic-based CVD prevention and management quality improvement…
Asia & Pacific | Middle East & North Africa | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ReviewPublication 2015Provider Costs for Cardiovascular Disease in Low-And Middle-Income Countries: A Systematic Review
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy …
The burden of cardiovascular disease (CVD) and related conditions is increasing in low- and middle-income countries. Policy makers need an understanding of the magnitude and drivers of the costs of cardiovascular disease related conditions to make decisions on how to allocate limited health resources. This systematic review of the published literature documents provider-incurred costs of treatment for cardiovascular diseases and risk conditions in low- and middle-income countries. Total costs of treatment were inflated to 2012 US dollars for comparability…
Asia & Pacific | Middle East & North Africa | Chronic Disease/Risk | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Asia & Pacific | Middle East & North Africa | Chronic Disease/Risk | Health Outcomes | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Global | Sub-Saharan Africa | Latin America & Caribbean -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Asia & Pacific | Middle East & North Africa | Chronic Disease/Risk | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Latin America & Caribbean -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Mental Health | Health Systems | Health/Medicine | Oceania -
ArticlePublication 2021Alleviating the Burden of Diabetes with Health Equity Funds: Economic Evaluation of the Health & Financial Risk Protection Benefits in Cambodia
This study examines the potential distributional health and financial impacts of implementing strategies to provide …
This study examines the potential distributional health and financial impacts of implementing strategies to provide financial coverage for diabetes services through Health Equity Funds (HEF) in Cambodia. Utilizing a Markov model, the trajectory of diabetes is projected over a 45-year period to estimate societal costs, health outcomes, and individual out-of-pocket expenditures associated with six HEF coverage strategies. Input parameters are derived from published literature and household survey data. Strategies covered different combinations of types of…
Asia & Pacific | Chronic Disease/Risk | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2020Impact of Cigarette Tax Increase in India
This article, published in Gates Open Research, examines the impact of a one-time large cigarette …
This article, published in Gates Open Research, examines the impact of a one-time large cigarette price increase, through an increase in excise tax, on health and financing outcomes in four Indian states. Extended cost-effectiveness analysis (ECEA) is used to estimate, across income quintiles, the life-years gained, treatment cost averted, number of men avoiding catastrophic health expenditures and extreme poverty, and additional tax revenue collected with a cigarette price increase to Indian Rupees (INR) 10 plus…
Asia & Pacific | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine -
ArticlePublication 2020Who Benefits Most from Extending Financial Protection for Cataract Surgery in Vietnam?: An ECEA
This study evaluated the potential impact, on health and financial protection, of eliminating medical and …
This study evaluated the potential impact, on health and financial protection, of eliminating medical and non-medical out-of-pocket costs associated with cataract surgery in Vietnam using extended cost-effectiveness analysis.
Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Health/Medicine -
ArticlePublication 2017Distributional Benefits of Tobacco Tax and Smoke-Free Workplaces in China
This study used the extended cost–effectiveness analysis (ECEA) to evaluate, across income quintiles of the …
This study used the extended cost–effectiveness analysis (ECEA) to evaluate, across income quintiles of the male population, the premature deaths averted, the change in tax revenues generated, and the financial risk protection procured, that would follow a 75% increase in cigarette prices through substantial increments in excise tax fully passed onto consumers, and a nationwide total implementation of workplace smoking bans. A 75% increase in cigarette prices would avert about 24 million premature deaths among…
Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Social Determinants | Policy/Regulation | Health/Medicine